Australia’s CSL to Buy Swiss Drugmaker Vifor for $11.7 Bln

ZURICH — Australian biopharmaceutical giant CSL Ltd said it would buy Swiss drugmaker Vifor Pharma AG for $11.7 billion, as it aims to diversify beyond its blood plasma collection business after taking a hit from COVID-19 curbs. Read More